LINC01423

Across TCGA pan-cancer cohorts, LINC01423 RNA is linked to patient survival in 21 of 34 cancer types, making it the most broadly survival-associated LINC01423 data layer.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher LINC01423 RNA is associated with better disease-free survival. In most high-consensus cancer types, elevated LINC01423 expression acts as an unfavorable survival marker, although some lineages such as LUAD and KIRP show a favorable association.

LUAD, UVM, and STAD are the cancer types where LINC01423 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Quartile	All	0.520	0.207	<.001	83	view →
UVM	DFS	Tertile	All	0.266	0.615	<.001	81	view →
STAD	DFS	Quartile	All	0.556	0.751	.010	54	view →
BRCA	DFS	Quartile	III,IV	0.804	0.931	.002	45	view →
ACC	DFS	Tertile	All	0.225	0.648	.002	38	view →
GBM	DFS	Tertile	All	0.129	0.317	.003	27	view →
KIRP	OS	Quartile	III,IV	1.000	0.570	.003	25	view →
UCS	OS	Tertile	IV	0.241	0.844	.024	18	view →
SARC	DFS	Median	All	0.537	0.683	.002	18	view →
CHOL	OS	Tertile	II,III,IV	0.024	0.601	.025	18	view →
LAML	DFS	Quartile	All	0.617	0.404	.018	12	view →
PAAD	OS	Tertile	All	0.228	0.543	.008	12	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 21 lineages.

LINC01423–LUAD (DFS)

Open the LUAD breakdown →